Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04112498
Title A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

urinary bladder cancer

hepatocellular carcinoma

Advanced Solid Tumor

renal cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

melanoma

gastric adenocarcinoma

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma

Therapies

Nivolumab + Relatlimab + rHuPH20

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.